Drug-induced liver injury in humans: the case of ximelagatran.
about
Idiosyncratic adverse drug reactions: current conceptsEvidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in manEnoxaparin-Induced Liver Injury: Case Report and Review of the Literature and FDA Adverse Event Reporting System (FAERS)Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting systemAn update on recent patents on thrombin inhibitors (2010 - 2013)Direct thrombin inhibitors.The fourth mammalian molybdenum enzyme mARC: current state of research.Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.Hypersensitivity reactions to modern antiplatelet and anticoagulant drugs.T cell-mediated hypersensitivity reactions to drugsA multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicityDesigning allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition.Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT studyRecent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.Predicting and preventing acute drug-induced liver injury: what's new in 2010?Drug-induced liver injury: a summary of recent advances.The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.New oral anticoagulants: a view from the laboratory.Latest advances in predicting DILI in human subjects: focus on biomarkers.Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation: dawn of a new era.A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.Novel oral anticoagulants: clinical pharmacology, indications and practical considerations.Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis.The mammalian molybdenum enzymes of mARC.Hepatotoxicity of New Oral Anticoagulants (NOACs).Non-cytochrome P450-mediated bioactivation and its toxicological relevance.Computational toxicology: Its essential role in reducing drug attrition.Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy.Postmarketing Safety Events Relating to New Drugs Approved in Brazil Between 2003 and 2013: A Retrospective Cohort Study.CYP1A1 and CYP1B1-mediated biotransformation of the antitrypanosomal methamidoxime prodrug DB844 forms novel metabolites through intramolecular rearrangement.HLA-DR7 and HLA-DQ2: Transgenic mouse strains tested as a model system for ximelagatran hepatotoxicitySafe and effective medicines for all: is personalized medicine the answer?Early Alterations of Bile Canaliculi Dynamics and the Rho Kinase/Myosin Light Chain Kinase Pathway Are Characteristics of Drug-Induced Intrahepatic Cholestasis.Dynamic imaging of adaptive stress response pathway activation for prediction of drug induced liver injury.Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: Systematic review and meta-analysis.
P2860
Q26824391-5C066B00-20B6-49DA-9807-CA1835490897Q28069617-76B1F503-8C43-4E26-87B3-05D825824FC9Q28074812-8EEA47BF-75A9-4334-9779-C9CB8D93EDE3Q28257188-02D6243F-1A65-40DA-9585-2614539B3E8BQ28299898-3AD03BDE-7D50-4912-9BCD-CAED872B6AEEQ33393692-AA308D01-B4AD-4D8D-B9BD-38B8FEFF825BQ34028677-9D7FE5C7-444D-4C31-8988-73452D3840FDQ34252907-D60705D0-6192-42C9-9C3E-DC77243C77F1Q34627780-612E2817-1078-47EC-81EE-F79ACD38624EQ34670994-C0850D16-20B6-42A4-AD3E-87435912562EQ34971993-769449EA-3CF8-40D6-AB62-254E0DF6D7E2Q36061736-169820FA-7D4B-4D70-843A-C9CCD417BDB8Q36157083-5DACE93E-4391-4510-B06D-08078C43C614Q36597715-10FBBE7A-C934-400A-873B-FF8FF05066AEQ37121662-364DB945-B35B-4B07-9621-C440925AE228Q37771029-B5AA3287-9BF9-48FF-AB03-9AEB83298AC4Q37867695-508CE80A-E175-4BB7-BBF2-3C04CFA18581Q37979858-FC256940-9447-4FAD-B29E-BF97CD83D968Q37992582-73C96A18-012F-4532-BA59-7A653CD58190Q38045377-FA40C8E4-D8FC-4D7C-BF74-F5D7DAC52B68Q38079915-3AF77E86-F2E6-4C71-94C6-5EE2F2590E85Q38087192-D9B28CAF-35BB-42B4-8F1F-092982B30065Q38101845-D4C30276-ED29-428D-A6F6-87C6B7DBAECFQ38183208-86088740-DFF2-4F72-B473-24CC497B23F5Q38271482-AA2EF022-8D3E-432F-962D-750606E4CAFBQ38542198-422FB6C3-BE82-461C-9FB1-BC692191F39EQ38929936-93CF290D-E2D8-44FA-87BC-B21AADF2253DQ38937780-51A31BED-5AA2-49CD-A7B9-14486144BB83Q39366146-4A6D9DC9-1057-45FD-BEB0-DFB13BEBEC5BQ39766399-3C800498-815D-4DD4-B7D4-39CA3D8D09CBQ40604485-171270DA-1F9B-40FA-8B92-0B91E0D552CEQ42054617-50482361-F3C5-44C8-B570-88537157429EQ42362078-8D99E6CD-C81E-4995-9D9C-F981767BFDA9Q44483899-1B071313-4616-4F5F-BB5A-AADDF2908D36Q51563626-6F82FB9F-736D-4226-9042-71FDC5F2D434Q52729055-30A0F202-2047-4DD9-AD55-434EB5BCAC6EQ55065699-EF50626B-E787-459B-8C8E-8BDB9013F3D8
P2860
Drug-induced liver injury in humans: the case of ximelagatran.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Drug-induced liver injury in humans: the case of ximelagatran.
@en
Drug-induced liver injury in humans: the case of ximelagatran.
@nl
type
label
Drug-induced liver injury in humans: the case of ximelagatran.
@en
Drug-induced liver injury in humans: the case of ximelagatran.
@nl
prefLabel
Drug-induced liver injury in humans: the case of ximelagatran.
@en
Drug-induced liver injury in humans: the case of ximelagatran.
@nl
P1476
Drug-induced liver injury in humans: the case of ximelagatran.
@en
P2093
T B Andersson
P304
P356
10.1007/978-3-642-00663-0_13
P577
2010-01-01T00:00:00Z